Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

NCT07192432 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Expressing Solid Tumors

Interventions

GENETIC: Dose Level 1, VNX-202
GENETIC: Dose Level 2, VNX-202
GENETIC: Dose Level 3, VNX-202
GENETIC: Dose Level 4, VNX-202

Sponsor

Vironexis Biotherapeutics Inc.